Farther Finance Advisors LLC Lowers Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Farther Finance Advisors LLC trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 637 shares of the company’s stock after selling 168 shares during the quarter. Farther Finance Advisors LLC’s holdings in IDEXX Laboratories were worth $263,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its stake in IDEXX Laboratories by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 453 shares of the company’s stock worth $187,000 after buying an additional 201 shares during the period. Sequoia Financial Advisors LLC grew its stake in IDEXX Laboratories by 6.2% during the fourth quarter. Sequoia Financial Advisors LLC now owns 1,685 shares of the company’s stock worth $697,000 after buying an additional 98 shares during the period. PFG Advisors grew its stake in IDEXX Laboratories by 0.7% during the fourth quarter. PFG Advisors now owns 7,465 shares of the company’s stock worth $3,086,000 after buying an additional 50 shares during the period. AGF Management Ltd. purchased a new stake in IDEXX Laboratories during the fourth quarter worth approximately $516,000. Finally, Inspire Advisors LLC grew its stake in IDEXX Laboratories by 15.2% during the fourth quarter. Inspire Advisors LLC now owns 1,241 shares of the company’s stock worth $513,000 after buying an additional 164 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on IDXX shares. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, Leerink Partners started coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Down 0.7 %

IDXX opened at $419.52 on Wednesday. The stock has a market capitalization of $34.12 billion, a PE ratio of 39.32, a P/E/G ratio of 3.41 and a beta of 1.39. The firm’s fifty day moving average price is $437.74 and its 200 day moving average price is $445.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.